Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi - 24/04/13
Correspondence to: Douglas Grossman, MD, PhD, Huntsman Cancer Institute, Suite 5262, 2000 Circle of Hope, Salt Lake City, UT 84112.Abstract |
Background |
Little is known about the recurrence/persistence rates of dysplastic nevi (DN) after biopsy, and whether incompletely removed DN should be re-excised to prevent recurrence.
Objective |
Our purpose was to determine the recurrence rates of previously biopsied DN, and to assess whether biopsy method, margin involvement, congenital features, epidermal location, and degree of dysplasia are associated with recurrence.
Methods |
Patients having a history of a “nevus biopsy” at least 2 years earlier were assessed for clinical recurrence. Slides of original lesions were re-reviewed by a dermatopathologist.
Results |
A total of 271 nevus biopsy sites were assessed in 115 patients. Of 195 DN with greater than 2 years of follow-up, 7 (3.6%) demonstrated recurrence on clinical examination. In all, 98 DN had a follow-up period of at least 4 years with no clinical recurrence. Of 61 benign nevus biopsy sites examined, clinical recurrence was observed in two (3.3%). For all nevi, recurrence was significantly associated with shave biopsy technique but not with nevus dysplasia or subtype, or the presence of positive margin or congenital features.
Limitations |
Most biopsies were performed in a pigmented lesion clinic at a single tertiary referral center. Determinations of nevus recurrence were made on clinical rather than histologic grounds, and follow-up times were limited in some cases.
Conclusion |
In this cohort, rates of clinical recurrence after biopsy of DN and benign nevi were extremely low. Re-excision of nevi, including mildly to moderately DN with a positive margin, may not be necessary.
Le texte complet de cet article est disponible en PDF.Key words : biopsy, dysplastic, nevi, recurrence
Plan
| Supported by the Department of Dermatology, the Huntsman Cancer Foundation, and the National Institutes of Health (Dr Grossman) |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 62 - N° 4
P. 591-596 - avril 2010 Retour au numéro
Article précédent
- Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles
- Neil Swanson, William Abramovits, Brian Berman, James Kulp, Darrell S. Rigel, Sharon Levy
- Dermatoscopy of pigmented Bowen’s disease
- Alan Cameron, Cliff Rosendahl, Philipp Tschandl, Elisabeth Riedl, Harald Kittler
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?